ImmunityBio's NAI+BCG Delivers More Durable Complete Responses in BCG-Unresponsive NMIBC at AUA 2026
ImmunityBio presented indirect treatment comparison analyses at AUA 2026 showing nogapendekin alfa inbakicept-pmln (NAI) plus BCG achieving higher and longer-lasting complete responses than nadofaragene firadenovec-vncg in BCG-unresponsive NMIBC with CIS (anytime CR 69.7% vs 53.4%; median CR duration 22.1 vs 9.7 months; cystectomy-free HR 0.40). In comparison with TAR-200, NAI+BCG had a higher 12‑month CR (49.2% vs 45.9%) and substantially fewer treatment-related adverse events (61.7% vs 83.5%) based on MAIC analyses. Results are from unanchored indirect comparisons and should be interpreted with caution, but support IL-15–driven, bladder-sparing immunotherapy potential in NMIBC with CIS. The company also cites ongoing BCG development efforts, including Tokyo strain and recombinant BCG programs.